8 research outputs found
Dupilumab is associated with lower rates of respiratory infections in patients with chronic rhinosinusitis with nasal polyps-Safety analysis from the SINUS-52 phase 3 trial
No full textA post hoc analysis of dupilumab efficacy in asthma patients with comorbid allergic rhinitis and chronic rhinosinusitis/nasal polyps from the LIBERTY ASTHMA QUEST study
No full textDupimulab reduced exacerbations and improved lung functions in patients with moderate-to-severe asthma and prior exacerbations: LIBERTY ASTHMA TRAVERSE study.
No full textSanofi and Regeneron Pharmaceuticals, Inc
Dupilumab reduced severe exacerbation rates and improved pre-bronchodilator Fev 1 in patients with moderate-to-severe asthma regardless of exacerbation history of 蠅1, 蠅2, or 蠅3 prior exacerbations: Liberty Asthma Traverse
No full textThis is the author accepted manuscript. The final version is available from the American Thoracic Society via the DOI in this record Sanofi and Regeneron Pharmaceuticals, Inc
Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to- severe type 2 inflammatory asthma by allergen sensitization status
No full textPhipatanakul W, Papadopoulos NG, Hernandez-Trujillo V, et al. Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to- severe type 2 inflammatory asthma by allergen sensitization status. In: Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 1-3 July 2022. Vol 78. Hoboken: Wiley; 2023: 5-6
Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status
No full textPhipatanakul W, Papadopoulos NG, Hernandez-Trujillo V, et al. Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status. Allergologie. 2022;45(8):604
